A Comprehensive Review of Estradiol, Progesterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in the Context of Laboratory Medicine to Support Women's Health
Top Cited Papers
- 18 April 2025
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 71 (8) , 842-857
Abstract
Background: There have been conflicting messages about the influence of female sex hormones on women's health, with historical messaging indicating that use of estrogen and/or progesterone in peri- or postmenopause poses a significant clinical risk to cisgender women. More recent guidance indicates that the benefit of hormone therapy (HT) outweighs the risks for symptomatic women. Exogenous estrogen use is also indicated for contraception and gender-affirming care. Despite the potential for broad applications, robust reference intervals for estradiol, progesterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are lacking, and guidelines indicate that measurement of 17-β-estradiol (E2), progesterone, LH, or FSH does not facilitate care in women who may be experiencing menopausal symptoms or women taking exogenous HT. Content: Here we review the physiological roles of estrogen, progesterone, LH, and FSH. We examine the modes of administration for estrogen and progesterone, clarify the nomenclature related to exogenous hormone use, and comprehensively review the literature for studies evaluating normal concentrations of these female gonadal axis hormones during the menstrual cycle. The content primarily focuses on cisgender women, but some aspects of these hormones in transgender women will also be discussed. Summary: Currently, E2, LH, FSH, and progesterone reference intervals for women remain incomplete. Although there are a variety of clinical indications that benefit women using HT, symptoms and shared decision-making should guide care. Collaborative efforts between clinicians and laboratory professionals to better define therapeutic or reference intervals for these hormones can advance women's health globally.Keywords
This publication has 72 references indexed in Scilit:
- The Women’s Health Initiative Randomized Trials and Clinical PracticeJAMA, 2024
- Menstrual Cycle Regularity and Length Across the Reproductive Lifespan and Risk of Cardiovascular DiseaseJAMA Network Open, 2022
- Association Between Reproductive Life Span and Incident Nonfatal Cardiovascular DiseaseJAMA Cardiology, 2020
- Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical TrialsJAMA, 2020
- Estradiol and Follicle-Stimulating Hormone as Predictors of Onset of Menopause Transition-Related Bone Loss in Pre- and Perimenopausal WomenJournal of Bone and Mineral Research, 2019
- Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause MortalityJAMA Cardiology, 2016
- Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized TrialsJAMA, 2013
- Long-Term Effects on Cognitive Function of Postmenopausal Hormone Therapy Prescribed to Women Aged 50 to 55 YearsJAMA Internal Medicine, 2013
- Ultralow-Dose Micronized 17β-Estradiol and Bone Density and Bone Metabolism in Older WomenJAMA, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002